A Phase 3 interventional study of KN3835 and Placebo in Flexible Hammertoe and Semi-flexible Hammertoe, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Recruiting at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.
Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: KN3835
Other: Placebo
Participants will receive KN3835.
Also known as: EN3835
Participants will receive placebo matching to KN3835.
Change From Baseline to Day 57 in Flexion Contracture as Measured by Goniometer
Time frame: Baseline, Day 57
Change From Baseline to Day 57 in the Foot Function Index (FFI) Difficulty Subscale Score
Time frame: Baseline, Day 57
Change From Baseline to Day 57 in the FFI Activity Limitation Subscale Score
Time frame: Baseline, Day 57
Change From Baseline to Day 57 in the Patient Global Impression of Severity (PGIS) HMT Overall Scale Score
Time frame: Baseline, Day 57
Change From Baseline up to Day 57 in Flexion Contracture as Measured by Goniometer
Time frame: Baseline, up to Day 57
Percent Change From Baseline up to Day 57 in Flexion Contracture as Measured by Goniometer
Time frame: Baseline, up to Day 57
Change From Baseline up to Day 57 in the FFI Pain Subscale Score
Time frame: Baseline, up to Day 57
Change From Baseline up to Day 57 in the FFI Difficulty Subscale Score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the FFI Activity Limitation Subscale Score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the FFI Total score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the PGIS Foot Pain Subscale Score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the PGIS Difficulty Subscale Score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the PGIS Activity Limitation Subscale Score
Time frame: Baseline, up to Day 57
Change from Baseline up to Day 57 in the PGIS HMT Overall Scale Score
Time frame: Baseline, up to Day 57
Number of Participants With >=1 Point Improvement in the Foot Patient Global Impression of Change (PGIC) Foot Pain Subscale Score
Time frame: Up to Day 57
Number of Participants With >=1 Point Improvement in the PGIC Difficulty Subscale Score
Time frame: Up to Day 57
Number of Participants With >=1 Point Improvement in the PGIC Activity Limitation Subscale Score
Time frame: Up to Day 57
Number of Participants With >=1 Point Improvement in the PGIC HMT Overall Scale Score
Time frame: Up to Day 57
Change from Baseline in the Pain Intensity Numeric Rating Scale (NRS) Score
Time frame: Up to Day 57
Number of Participants With >=1 Point Improvement in the Clinician Global Impression of Change (CGIC) Scale Score
Time frame: Up to Day 57
Number of Participants With >=1 Point Improvement in the Subject Satisfaction with Treatment Scale
Time frame: Up to Day 57
Number of Participants With a ≥ 30% reduction in Flexion Contracture as measured by Goniometry
Time frame: Baseline to Day 57
Number of Participants With a ≥ 50% reduction in Flexion Contracture as measured by Goniometry
Time frame: Baseline to Day 57
Number of Participants With TEAEs
Time frame: Baseline to Day 57
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase
Endo USA Inc., a Keenova Therapeutics Company →